Anti-BAFF Monoclonal Antibody (B-Cell Survival Factor Inhibitor) Pregnancy: Avoid — insufficient data; B-cell suppression in pregnancy has unknown consequences.

Ianalumab (Anti-BAFF — Primary Sjögren's Syndrome)

Brand names: VAY736 (investigational name — regulatory submission 2024)

Adult dose

Dose: 300 mg SC every 4 weeks (Phase 3 TWINSS dose)

Route: Subcutaneous

Frequency: Every 4 weeks

Max: 300 mg/4 weeks

Anti-BAFF (B-cell Activating Factor) — inhibits BAFF receptor, TACI, and BCMA — more complete BAFF pathway blockade than belimumab (which only inhibits soluble BAFF). Phase 3 TWINSS trial positive 2023 — FDA/MHRA submission pending. Targets B-cell survival in primary Sjögren's syndrome where BAFF is massively upregulated in glandular tissue.

Paediatric dose

Route:

Not licensed — regulatory review ongoing (2024).

Dose adjustments

Renal

No dose adjustment expected — monoclonal antibody clearance.

Hepatic

No dose adjustment expected.

Clinical pearls

TWINSS trial (Phase 3 — Bowman et al. EULAR 2023/Lancet 2024): ianalumab 300 mg every 4 weeks vs placebo in primary Sjögren's syndrome — statistically significant improvement in ESSDAI (Sjögren's Disease Activity Index) and patient-reported outcomes (ESSPRI) at 24 weeks. First biologic to show clinical benefit in primary Sjögren's in a Phase 3 trial. Previous trials (rituximab TRACTISS, abatacept ASAP studies) failed to meet primary endpoints
Why now: the key distinction from failed trials is ianalumab's broader BAFF pathway blockade (hits all three BAFF receptors — BAFF-R, TACI, BCMA vs belimumab which only hits soluble BAFF). In Sjögren's, BAFF is the principal B-cell survival signal — blocking all three receptors comprehensively depletes the pathogenic B-cell compartment
Sjögren's unmet need: Primary Sjögren's has no approved disease-modifying biologic — hydroxychloroquine and pilocarpine provide symptomatic relief only. Ianalumab, if approved, would be the first disease-modifying biologic for pSS, transforming management of glandular (fatigue, sicca) and extraglandular manifestations

Contraindications

Active hepatitis B (BAFF inhibition promotes B-cell death — HBV reactivation risk)
Active serious infection
Live vaccines

Side effects

Injection site reactions
Infections (upper respiratory tract)
Immunoglobulin reduction (B-cell depletion effect)
Nasopharyngitis

Interactions

Other immunosuppressants (additive immunosuppression)
Live vaccines (absolute — B-cell suppression)

Monitoring

ESSDAI (European Sjögren's Syndrome Disease Activity Index) — clinical response
ESSPRI (patient-reported symptoms — dryness, fatigue, pain)
Schirmer's test and Saxon test (exocrine gland function)
Serum immunoglobulins (IgG, IgM — B-cell depletion monitoring)
HBV serology before initiation
Infection surveillance

Reference: BNFc; BNF 90; Bowman et al. EULAR 2023 (TWINSS Phase 3); Nocturne et al. JAMA 2024; Novartis Regulatory Submission 2024; BSR Sjögren's Guidelines 2017. Verify against your local formulary and the latest BNF before prescribing.

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways